Infographics

Explore our summarised infographics.

Prescribing information for DOVATO (dolutegravir/lamivudine) can be found here.
Prescribing information for VOCABRIA▼ (cabotegravir) + REKAMBYS▼ (rilpivirine) can be found here.

Results:

Showing results for

DOVATO (dolutegravir/lamivudine) Data from CROI 2026
DOVATO

DOVATO (dolutegravir/lamivudine) Data from CROI 2026

Data from PASO DOBLE and a naïve meta-analysis from CROI 2026

View infographic

Dovato (dolutegravir/lamivudine): 5 Years Data
DOVATO

DOVATO (dolutegravir/lamivudine): 5 Years Data

5 Years of Clinical and Real World Evidence Data

View infographic

DOVATO (dolutegravir/lamivudine) 96Wk Data from PASO DOBLE
DOVATO

DOVATO (dolutegravir/lamivudine) 96Wk Data from PASO DOBLE

Data from PASO DOBLE from EACS 2025

View infographic

DOVATO (dolutegravir/lamivudine) Data from VOLITION and D2ARLING
DOVATO

DOVATO (dolutegravir/lamivudine) Data from VOLITION and D2ARLING

Data from VOLITION and D2ARLING from IAS 2025

View infographic

Other resources

ViiV Exchange Videos
RESOURCES

Videos and Recordings

View videos

ViiV Exchange Slide Sets
RESOURCES

Slide Sets

View Slide Sets

Podcasts
RESOURCES

Podcasts

Listen to podcasts

PM-GB-HVX-WCNT-220003 | June 2026

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.